About: An overview of the pathogenic mechanisms involved in severe cases of COVID-19 infection, and the proposal of salicyl-carnosine as a potential drug for its treatment

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: An overview of the pathogenic mechanisms involved in severe cases of COVID-19 infection, and the proposal of salicyl-carnosine as a potential drug for its treatment Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	An overview of the pathogenic mechanisms involved in severe cases of COVID-19 infection, and the proposal of salicyl-carnosine as a potential drug for its treatment
Creator	Fedorova, Tatiana Kazanskaya, Rogneda Khutorova, Anastasiya Lopachev, Alexander
source	Elsevier; Medline; PMC
abstract	Multiple organ failure in COVID-19 patients is a serious problem which can result in a fatal outcome. Damage to organs and tissues, including general lung dysfunction, develops as a consequence of ischemia, which, in turn, is caused by thrombosis in small blood vessels and hypoxia, leading to oxidative stress and inflammation. Currently, research is underway to screen existing drugs for antioxidant, antiplatelet and anti-inflammatory properties. Having studied the available publications concerning the mechanisms of damage to tissues and organs of patients with COVID-19, as well as the available treatment strategies, we propose to investigate salicyl-carnosine as a potential drug for treating COVID-19 patients. In a recent study, we described the drug’s synthesis procedure, and showed that salicyl-carnosine possesses antioxidant, anti-inflammatory, and antiplatelet effects. Therefore, it can simultaneously act on the three pathogenetic factors involved in tissue and organ damage in COVID-19. Thus, we propose to consider salicyl-carnosine as a potential drug for the treatment of patients with severe cases of COVID-19 infection.
has issue date	2020-08-01(xsd:dateTime)
bibo:doi	10.1016/j.ejphar.2020.173457
bibo:pmid	32750366
has license	no-cc
sha1sum (hex)	efe5a71eb8193fdf5e9ad1e94c6a7d0f3cca0024
schema:url	https://doi.org/10.1016/j.ejphar.2020.173457
resource representing a document's title	An overview of the pathogenic mechanisms involved in severe cases of COVID-19 infection, and the proposal of salicyl-carnosine as a potential drug for its treatment
has PubMed Central identifier	PMC7395637
has PubMed identifier	32750366
schema:publication	Eur J Pharmacol
resource representing a document's body	covid:efe5a71eb8193fdf5e9ad1e94c6a7d0f3cca0024#body_text
is schema:about of	named entity 'severe' named entity 'carnosine' named entity 'carnosine' named entity 'Roche' named entity 'inflammation' named entity 'iron' named entity 'COVID' named entity 'COVID' named entity 'losartan' named entity 'formation of blood clots' named entity 'Angiotensin II' named entity 'ARDS' named entity 'virus' named entity 'clinical practice' named entity 'endothelial' named entity 'IL-6' named entity 'van Hecke' named entity 'anti-inflammatory' named entity 'COVID-19' named entity 'carnosine' named entity 'receptor' named entity 'IL-1β' named entity 'endothelium' named entity 'pro-inflammatory cytokines' named entity 'aspirin' named entity 'pulmonary alveoli' named entity 'drug action' named entity 'cytokine storm' named entity 'viral load' named entity 'ligand' named entity 'dashed' named entity 'IL-6' named entity 'chelation' named entity 'oxidative stress' named entity 'lungs' named entity 'Patent' named entity 'carnosine' named entity 'deacetylated' named entity 'oxidative damage' named entity 'carnosine' named entity 'tocilizumab' named entity 'erythrocytes' named entity 'neutrophils' named entity 'inflammation' named entity 'coagulation' named entity 'cytokine release syndrome' named entity 'hydrolysis' named entity 'multiple organ failure' named entity 'oxidative stress' named entity 'inflammation' named entity 'carnosine' named entity 'treatment of patients' named entity 'vitamin' named entity 'covid-19' named entity 'ACE2' named entity 'Baicalin' named entity 'anti-inflammatory' named entity 'oxidative stress' named entity 'tissue damage' named entity 'vitamin' named entity 'bloodstream' named entity 'extracellular' named entity 'anti-oxidative' named entity 'Aspirin' named entity 'carnosine' named entity 'oxidative stress' named entity 'tissue damage' named entity 'inflammation' named entity 'interferon' named entity 'pro-inflammatory cytokines' named entity 'vasodilatory' named entity 'Oral administration' named entity 'Erythropoietin' named entity 'platelet aggregation' named entity 'Hemoglobin' named entity 'antithrombotic' named entity 'COVID-19' named entity 'respiratory burst'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software